Diagnostic utility of immunohistochemistry in concordance with mRNA analysis of PRAME in the stratification of high-risk uveal melanoma patients.
BAP1
Immunohistochemistry
PRAME
Real-time PCR
Uveal melanoma
Journal
Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
13
08
2022
accepted:
04
10
2022
pubmed:
26
10
2022
medline:
7
1
2023
entrez:
25
10
2022
Statut:
ppublish
Résumé
Existing clinical indicators for metastatic risk classification and patient treatment of uveal melanoma (UM) in the Asian population are limited. Preferentially expressed antigen in melanoma (PRAME) has gained attention in the prognosis of cancers and considered as a potential biomarker in many tumors including UM. Therefore, this study investigated the expression of PRAME and its association with loss of nuclear BAP1 (nBAP1) as well as its correlation with clinicopathological parameters and patient outcome. Immunohistochemical expression of PRAME and BAP1 proteins were assessed in 66 prospective cases of UM. mRNA expression level was measured by quantitative real-time PCR. Kaplan-Meier curves and Cox proportional hazard models were used to analyze the correlation of protein expression with clinicopathological parameters, metastasis-free survival and overall survival. Nuclear PRAME (nPRAME) expression and loss of nBAP1 were observed in 24 and 62% cases, respectively. PRAME mRNA expression level was found to be upregulated in 64% (7/11) of metastatic patients. mRNA and immunoexpression of nPRAME were statistically significant with many clinicopathological high-risk factors. On univariate and multivariate analyses, high mitotic activity, extraocular invasion and presence of nPRAME expression were statistically significant (p < 0.05). On Kaplan-Meier survival analysis, patients expressing PRAME had significantly reduced metastasis-free survival (MFS) and overall survival (OS). MFS and OS were also reduced in patients expressing PRAME along with loss of nBAP1. Our data show that nPRAME expression, in combination with loss of nBAP1, could be a useful predictive biomarker in the therapeutic management of UM patients at high risk.
Identifiants
pubmed: 36282437
doi: 10.1007/s13577-022-00808-z
pii: 10.1007/s13577-022-00808-z
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
PRAME protein, human
0
RNA, Messenger
0
Transcription Factors
0
BAP1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
342-352Subventions
Organisme : Indian Council of Medical Research
ID : F. No. 5/4/6/3/OPH/2019-NCD-II
Informations de copyright
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.
Références
Lee WS, Lee J, Choi JJ, Kang HG, Lee SC, Kim JH. Paired comparisons of mutational profiles before and after brachytherapy in asian uveal melanoma patients. Sci Rep. 2021;11(1):18594. https://doi.org/10.1038/s41598-021-98084-8 .
doi: 10.1038/s41598-021-98084-8
Branisteanu DC, Bogdanici CM, Branisteanu DE, Maranduca MA, Zemba M, Balta F, et al. Uveal melanoma diagnosis and current treatment options (Review). Exp Ther Med. 2021;22(6):1428. https://doi.org/10.3892/etm.2021.10863 .
doi: 10.3892/etm.2021.10863
Jager MJ, Shields CL, Cebulla CM, Abdel-Rahman MH, Grossniklaus HE, Stern MH, et al. Uveal melanoma. Nat Rev Dis Primers. 2020;6(1):24. https://doi.org/10.1038/s41572-020-0158-0 .
doi: 10.1038/s41572-020-0158-0
Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9. https://doi.org/10.1158/0008-5472.Can-04-1750 .
doi: 10.1158/0008-5472.Can-04-1750
Harbour JW. A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. Methods Mol Biol. 2014;1102:427–40. https://doi.org/10.1007/978-1-62703-727-3_22 .
doi: 10.1007/978-1-62703-727-3_22
van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014;98(12):1738–43. https://doi.org/10.1136/bjophthalmol-2014-305047 .
doi: 10.1136/bjophthalmol-2014-305047
Aaberg TM, Covington KR, Tsai T, Shildkrot Y, Plasseraud KM, Alsina KM, et al. Gene expression profiling in uveal melanoma: five-year prospective outcomes and meta-analysis. Ocul Oncol Pathol. 2020;6(5):360–7. https://doi.org/10.1159/000508382 .
doi: 10.1159/000508382
Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, et al. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016;22(5):1234–42. https://doi.org/10.1158/1078-0432.Ccr-15-2071 .
doi: 10.1158/1078-0432.Ccr-15-2071
Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. PRAME expression in melanocytic tumors. Am J Surg Pathol. 2018;42(11):1456–65. https://doi.org/10.1097/pas.0000000000001134 .
doi: 10.1097/pas.0000000000001134
Szczepanski MJ, DeLeo AB, Łuczak M, Molinska-Glura M, Misiak J, Szarzynska B, et al. PRAME expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol. 2013;49(2):144–51. https://doi.org/10.1016/j.oraloncology.2012.08.005 .
doi: 10.1016/j.oraloncology.2012.08.005
Thongprasert S, Yang PC, Lee JS, Soo R, Gruselle O, Myo A, et al. The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients. Lung Cancer. 2016;101:137–44. https://doi.org/10.1016/j.lungcan.2016.09.006 .
doi: 10.1016/j.lungcan.2016.09.006
Epping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. Br J Cancer. 2008;99(3):398–403. https://doi.org/10.1038/sj.bjc.6604494 .
doi: 10.1038/sj.bjc.6604494
Lezcano C, Pulitzer M, Moy AP, Hollmann TJ, Jungbluth AA, Busam KJ. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. Am J Surg Pathol. 2020;44(4):503–8. https://doi.org/10.1097/pas.0000000000001393 .
doi: 10.1097/pas.0000000000001393
Toyama A, Siegel L, Nelson AC, Najmuddin M, Bu L, LaRue R, et al. Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas. Mod Pathol. 2019;32(12):1727–33. https://doi.org/10.1038/s41379-019-0335-4 .
doi: 10.1038/s41379-019-0335-4
Lohman ME, Steen AJ, Grekin RC, North JP. The utility of PRAME staining in identifying malignant transformation of melanocytic nevi. J Cutan Pathol. 2021;48(7):856–62. https://doi.org/10.1111/cup.13958 .
doi: 10.1111/cup.13958
Coupland S, Kalirai H, Taktak A, Eleuteri A, Damato B. Re: Gelmi et al adding the cancer genome atlas chromosome classes to American Joint Committee on Cancer System offers more precise prognostication in uveal melanoma. Ophthalmology. 2022. https://doi.org/10.1016/j.ophtha.2022.02.031 .
doi: 10.1016/j.ophtha.2022.02.031
Kapoor AG, Kaliki S, Vempuluru VS, Jajapuram SD, Ali MH, Mohamed A. (2020) Posterior uveal melanoma in 321 Asian Indian patients: analysis based on the 8th edition of American Joint Committee Cancer classification. Int Ophthalmol. 40(11): 3087-3096 https://doi.org/10.1007/s10792-020-01494-2
Jha J, Singh MK, Singh L, Pushker N, Bajaj MS, Sen S, et al. Expression of BAP1 and ATM proteins: association with AJCC tumor category in uveal melanoma. Ann Diagn Pathol. 2020;44: 151432. https://doi.org/10.1016/j.anndiagpath.2019.151432 .
doi: 10.1016/j.anndiagpath.2019.151432
Ahmadian SS, Dryden IJ, Naranjo A, Toland A, Cayrol RA, Born DE, et al. Preferentially expressed antigen in melanoma immunohistochemistry labeling in uveal melanomas. Ocul Oncol Pathol. 2022;8(2):133–40. https://doi.org/10.1159/000524051 .
doi: 10.1159/000524051
See TR, Stålhammar G, Phillips S, Grossniklaus HE. BAP1 immunoreactivity correlates with gene expression class in uveal melanoma. Ocul Oncol Pathol. 2020;6(2):129–37. https://doi.org/10.1159/000502550 .
doi: 10.1159/000502550
Kaštelan S, Antunica AG, Oresković LB, Pelčić G, Kasun E, Hat K. Immunotherapy for uveal melanoma - current knowledge and perspectives. Curr Med Chem. 2020;27(8):1350–66. https://doi.org/10.2174/0929867326666190704141444 .
doi: 10.2174/0929867326666190704141444
Schefler AC, Koca E, Bernicker EH, Correa ZM. Relationship between clinical features, GEP class, and PRAME expression in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2019;257(7):1541–5. https://doi.org/10.1007/s00417-019-04335-w .
doi: 10.1007/s00417-019-04335-w
Cai L, Paez-Escamilla M, Walter SD, Tarlan B, Decatur CL, Perez BM, et al. Gene expression profiling and PRAME status versus tumor-node-metastasis staging for prognostication in uveal melanoma. Am J Ophthalmol. 2018;195:154–60. https://doi.org/10.1016/j.ajo.2018.07.045 .
doi: 10.1016/j.ajo.2018.07.045
Ikeda H, Lethé B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity. 1997;6(2):199–208. https://doi.org/10.1016/s1074-7613(00)80426-4 .
doi: 10.1016/s1074-7613(00)80426-4
Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, et al. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens. J Clin Invest. 2017;127(7):2705–18. https://doi.org/10.1172/jci92335 .
doi: 10.1172/jci92335
Wadelin F, Fulton J, McEwan PA, Spriggs KA, Emsley J, Heery DM. Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia. Mol Cancer. 2010;9:226. https://doi.org/10.1186/1476-4598-9-226 .
doi: 10.1186/1476-4598-9-226
Baba H, Kanda M, Sawaki K, Umeda S, Miwa T, Shimizu D, et al. PRAME as a potential biomarker for liver metastasis of gastric cancer. Ann Surg Oncol. 2020;27(6):2071–80. https://doi.org/10.1245/s10434-019-07985-6 .
doi: 10.1245/s10434-019-07985-6
Ding K, Wang XM, Fu R, Ruan EB, Liu H, Shao ZH. PRAME gene expression in acute leukemia and its clinical significance. Cancer Biol Med. 2012;9(1):73–6. https://doi.org/10.3969/j.issn.2095-3941.2012.01.013 .
doi: 10.3969/j.issn.2095-3941.2012.01.013
Cazzato G, Mangialardi K, Falcicchio G, Colagrande A, Ingravallo G, Arezzo F, et al. Preferentially expressed antigen in melanoma (PRAME) and human malignant melanoma: a retrospective study. Genes. 2022;13(3):545. https://doi.org/10.3390/genes13030545 .
doi: 10.3390/genes13030545
Zhang YH, Lu AD, Yang L, Li LD, Chen WM, Long LY, et al. PRAME overexpression predicted good outcome in pediatric B-cell acute lymphoblastic leukemia patients receiving chemotherapy. Leuk Res. 2017;52:43–9. https://doi.org/10.1016/j.leukres.2016.11.005 .
doi: 10.1016/j.leukres.2016.11.005
Al-Khadairi G, Naik A, Thomas R, Al-Sulaiti B, Rizly S, Decock J. PRAME promotes epithelial-to-mesenchymal transition in triple negative breast cancer. J Transl Med. 2019;17(1):9. https://doi.org/10.1186/s12967-018-1757-3 .
doi: 10.1186/s12967-018-1757-3
Field MG, Durante MA, Decatur CL, Tarlan B, Oelschlager KM, Stone JF, et al. Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas. Oncotarget. 2016;7(37):59209–19. https://doi.org/10.18632/oncotarget.10962 .
doi: 10.18632/oncotarget.10962
Bronkhorst IH, Jager MJ. Uveal melanoma: the inflammatory microenvironment. J Innate Immun. 2012;4(5–6):454–62. https://doi.org/10.1159/000334576 .
doi: 10.1159/000334576
Mlecnik B, Bindea G, Pagès F, Galon J. Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 2011;30(1):5–12. https://doi.org/10.1007/s10555-011-9270-7 .
doi: 10.1007/s10555-011-9270-7
Xu Q, Wang C, Yuan X, Feng Z, Han Z. Prognostic value of tumor-infiltrating lymphocytes for patients with head and neck squamous cell carcinoma. Transl Oncol. 2017;10(1):10–6. https://doi.org/10.1016/j.tranon.2016.10.005 .
doi: 10.1016/j.tranon.2016.10.005
Li JF, Chu YW, Wang GM, Zhu TY, Rong RM, Hou J, et al. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int. 2009;103(3):399–405. https://doi.org/10.1111/j.1464-410X.2008.08151.x .
doi: 10.1111/j.1464-410X.2008.08151.x